During the primary series doses of the COVID-19 vaccination, the majority of patients (n = 28, 53%) were on stable treatment with aminosalicylates, followed by 14 (27%) on anti-TNFα monoclonal antibodies (n = 5 infliximab, n = 6 golimumab, n = 3 adalimumab), while 5 (9%) were treated with anti-α4β7 integrin monoclonal antibodies (vedolizumab). The gene discussed is TNF; the disease is COVID-19.